FOLD №28 — TB-500 Lys3–Glu6 Lactam Cyclization

Verdict: REFINED | Class: REGENERATIVE | Target: Beta-actin (P60709)

Mechanism of Action

TB-500 (Ac-LKKTETQ) is the minimal bioactive heptapeptide fragment of thymosin β4, a 43-residue G-actin-sequestering protein. Its mechanism centers on the N-terminal LKKT WH2-like motif, which engages subdomains 1 and 3 of monomeric G-actin, preventing filament polymerization and making actin available for cell-motility, wound-healing, and angiogenic signaling cascades. Downstream effects documented in animal models and inferred from full-length Tβ4 biology include accelerated tissue repair, enhanced angiogenesis, integrin-mediated ECM remodeling, and anti-inflammatory modulation. The parent peptide is rapidly degraded in human serum (Rahaman et al., 2024), with Ac-LK and Ac-LKK as predominant metabolites that lack wound-healing activity — establishing that the full heptapeptide scaffold, particularly the LKKTE core, is required for function.

Performance Applications

TB-500 is investigated in the regenerative and sports-performance communities for:

• Tissue repair: accelerated healing of muscle, tendon, and connective tissue injuries
• Angiogenesis: promotion of new capillary formation in ischemic or injured tissue
• Anti-fibrotic activity: reduction of scarring secondary to injury or inflammation
• Cell migration: enhancement of keratinocyte and endothelial cell motility relevant to wound closure

⚠️ No human clinical trials have validated TB-500 for any of these applications. All evidence derives from animal models or in vitro systems. This peptide is on WADA's prohibited list.

Modification Rationale

The lactam bridge is designed to address two co-existing liabilities of native TB-500:

1. Conformational disorder. As a free heptapeptide in solution, TB-500 is expected to populate a disordered ensemble. Binding to G-actin requires adoption of a helical/turn conformation — an entropic penalty that limits effective affinity. NMR and crystallographic data from full-length Tβ4 show that the LKKTETQ segment folds against actin with Lys-3 and Glu-6 on the same helical face, making them ideal anchor points for an i,i+3 lactam staple — one of peptide chemistry's most established helix-nucleating strategies.

2. Proteolytic vulnerability. Rahaman et al. (2024) demonstrated rapid serum cleavage of TB-500, with loss of the pharmacologically active LKKTE sequence. A macrocyclic bridge across the Lys3–Glu6 region sterically shields the central backbone and constrains the ring into a conformation that is less accessible to protease active sites.

Design constraints respected:

• Lys-2 is deliberately left unmodified to preserve the LKKT cationic actin-contact surface
• The cyclization spans only residues 3–6, leaving Leu-1, Lys-2, and Gln-7 as free termini
• The Glu-6 γ-carboxylate is consumed in the lactam bond, removing one negative charge from the ring but retaining the overall backbone register

Divergence from prior lab work: Fold №7 (N-terminal acetylation, REFINED, pLDDT 0.87) established the Ac-LKKTETQ scaffold as the structurally validated parent. The present distillation is best understood as a second-generation modification layered onto that scaffold — combining conformational constraint with the N-terminal capping geometry proven in Fold №7. Fold №16 (Lys-2→Orn, DISCARDED, pLDDT 0.80) attempted to address proteolysis by reducing the K2-K3 dibasic motif; that approach was abandoned and, critically, it touched the pharmacologically essential Lys-2 — a lesson directly incorporated into the present design, which leaves Lys-2 entirely intact.

Predicted Properties (Favourable Changes from Native)

Key structural finding: The predicted structure places the KTET ring in a compact, helically biased turn, while the LK N-terminal dipeptide and Gln-7 remain extended and solvent-exposed — precisely the geometry the design hypothesis required. The LKKT actin-contact face is accessible.

⚠️ All values are computational predictions or sequence-based heuristic estimates. No experimental data exist for this analog. Binding affinity, serum half-life, and biological activity have not been measured.

Suggested Next Steps

Computational (near-term):

1. Ensemble docking — Run multiple AlphaFold2-multimer or Rosetta FlexPepDock trajectories to generate a conformational ensemble of the lactam-bridged peptide–actin complex; ipTM 0.51 from a single run warrants ensemble confirmation before wet-lab synthesis investment.
2. MD simulation — 100–500 ns explicit-solvent molecular dynamics of both native and bridged TB-500 free in solution to quantify RMSF reduction and bioactive conformer population — the key mechanistic claim that cannot be addressed by static structure prediction alone.
3. Protease docking — Model the lactam-bridged variant against trypsin and serine endopeptidases active in human serum to test whether the bridge sterically occludes the dominant cleavage site(s); this will help resolve the uncertainty about whether the K2-K3 bond or the TET backbone is the primary proteolytic soft spot.

Chemistry (if computational signal strengthens): 4. Solid-phase synthesis — Prepare the lactam-bridged analog via Fmoc SPPS with orthogonal Lys(Alloc)/Glu(OAllyl) protection, on-resin cyclization with Pd(0), and N-terminal acetylation (to match the Fold №7 validated scaffold). Confirm ring closure by HRMS and 2D NMR (TOCSY/NOESY). 5. Serum stability assay — Incubate bridged vs. native Ac-LKKTETQ in human serum at 37°C, track metabolite formation by LC-Q-Exactive MS/MS using the Rahaman et al. (2024) protocol. This is the single most informative first wet-lab experiment.

Biology (downstream): 6. G-actin binding assay — SPR or fluorescence polarization with purified beta-actin to measure Kd for bridged vs. native TB-500; this would be the first quantitative actin-binding measurement for any TB-500 variant. 7. Scratch wound assay — HaCaT or HUVEC cells, standard wound-healing readout, to test whether the conformationally constrained analog retains or improves wound-closure activity at equimolar concentrations.

Cross-fold integration: A logical next distillation would combine the N-terminal acetylation of Fold №7 with the lactam bridge of Fold №28 into a single molecule (Ac-LK-cyclo(KTET)-Q), modeling whether the acetyl cap and the macrocycle cooperate or interfere structurally. This would complete a three-point SAR triangle on TB-500 within the lab.

FOLD №28 | Alembic Labs | In silico prediction only — not medical advice. No wet-lab data exist for this analog. Requires experimental validation before any biological conclusions can be drawn.